Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046353 | 0.98 | GABRA1 (0.32) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL4064043 | 0.85 | MEN1 (0.30) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4056255 | 0.85 | GABRA1 (0.32) | GABRA1GABRB2KDM4EMEN1MAPT | |
| Hydrochloric Acid SCHEMBL7189983 | 0.84 | — | — | |
| SCHEMBL7048957 | 0.83 | GABRA1 (0.32) | GABRA1GABRB2 | |
| Fluoride SCHEMBL7640201 | 0.82 | — | — | |
| Fluoride SCHEMBL7643007 | 0.82 | GABRA1 (0.32) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL2517398 | 0.81 | — | — | |
| SCHEMBL5346836 | 0.81 | GABRA1 (0.31) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL272677 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053263-B1 | CATALYST SYSTEM | BASELL POLYOLEFINE GMBH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-1058694-B1 | Catalyst system, method for its production and its use for the polymerisation of olefins | BASELL POLYOLEFINE GMBH (DE) | 2003-04-09 | — | — | EP | claimed |
| US-6482902-B1 | Catalyst system | TARGOR GMBH (DE) | 2002-11-19 | — | — | US | claimed |
| US-6391989-B1 | COORDINATION CATALYST ON SUPPORT; POLYMERIZATION OF ALPHA-OLEFINS | BASELL POLYPROPYLEN GMBH (DE) | 2002-05-21 | — | — | US | claimed |
| WO-2014070655-A1 | SUPPORTED METALLOCENE CATALYST SYSTEMS AND METHODS OF PREPARATION THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140121341-A1 | Supported Metallocene Catalyst Systems and Methods of Preparation Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2014-05-01 | — | — | US | disclosed |
| US-7202190-B1 | Supported catalyst system for the polymerization of olefins | TARGOR GMBH (DE) | 2007-04-10 | — | — | US | disclosed |
| US-7101940-B2 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-09-05 | — | — | US | disclosed |
| US-7034173-B2 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-04-25 | — | — | US | disclosed |
| US-6953829-B2 | Catalyst system and the use thereof | BASELL POLYOLEFINE GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-6949614-B1 | Catalyst system | BASELL POLYOLEFINE GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| US-6900343-B1 | Method for the purification of metallocenes | BASELL POLYOLEFINE GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| US-6482902-B1 | Catalyst system | TARGOR GMBH (DE) | 2002-11-19 | — | — | US | disclosed |
| US-6417302-B1 | REACTION PRODUCT OF DI(PENTAFLUOROPHENYL) BORINIC ACID AND ORGANOALUMINUM COMPOUND; OLEFIN POLYMERIZATION COORDINATION CATALYSTS | BASELL POLYOLEFINE GMBH (DE) | 2002-07-09 | — | — | US | disclosed |
| US-6407189-B1 | USING ORGANOMETALLIC COMPOUNDS AS CATALYST | CLARIANT GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-6391989-B1 | COORDINATION CATALYST ON SUPPORT; POLYMERIZATION OF ALPHA-OLEFINS | BASELL POLYPROPYLEN GMBH (DE) | 2002-05-21 | — | — | US | disclosed |
| US-20020058765-A1 | Catalyst system for the polymerization of olefins | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-16 | — | — | US | disclosed |
| US-6271164-B1 | METALLOCENE CATALYST | LYONDELL CHEMICAL TECHNOLOGY, L.P. | 2001-08-07 | — | — | US | disclosed |
| US-6177526-B1 | METALLOCENE; COCATALYST; MODIFIED OXIDE CONTAINS ORGANIC SILICON RADICALS CONTAINING AT LEAST ONE OF THE GROUPS NITROGEN, FLUORINE, PHOSPHORUS OR SULFUR. | TARGOR GMBH (DE) | 2001-01-23 | — | — | US | disclosed |
| US-6177376-B1 | REACTING METALLOCENE WITH ORGANOLITHIUM COMPOUND AND GRIGNARD COMPOUND, ACTIVATION, CONTACTING WITH SUPPORT | TARGOR GMBH (DE) | 2001-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058765-A1 | Catalyst system for the polymerization of olefins | MAOA, MAOB, MSMO1 | GABRA1 2975/4885GABRB2 2881/4885KDM4E 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.